Jane Street Group, LLC Oncternal Therapeutics, Inc. Transaction History

Jane Street Group, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.29 - $0.48 $3,177 - $5,259	-10,957 Reduced 51.57%	10,288 $3,000
Q2 2023 Aug 14, 2023	BUY	$0.28 - $0.79 $5,948 - $16,783	21,245 New	21,245 $7,000
Q1 2022 May 17, 2022	SELL	$1.37 - $2.43 $17,883 - $31,721	-13,054 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$2.27 - $4.39 $1,100 - $2,129	-485 Reduced 3.58%	13,054 $30,000
Q3 2021 Nov 16, 2021	SELL	$3.37 - $4.76 $15,451 - $21,824	-4,585 Reduced 25.3%	13,539 $57,000
Q2 2021 Aug 16, 2021	SELL	$4.75 - $9.39 $23,099 - $45,663	-4,863 Reduced 21.16%	18,124 $86,000
Q1 2021 May 18, 2021	BUY	$4.59 - $9.04 $105,510 - $207,802	22,987 New	22,987 $191,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.